# IV Iron Risks and Low-Dose AML Gains Page: https://stenobird.com/podcast/blood-podcast-664776/iv-iron-risks-and-low-dose-aml-gains Text version: https://stenobird.com/podcast/blood-podcast-664776/iv-iron-risks-and-low-dose-aml-gains.md Podcast: [Blood Podcast](https://stenobird.com/podcast/blood-podcast-664776) Published: 2026-07-02T16:00:00+00:00 Episode link: https://share.transistor.fm/s/c7970701 Audio file: https://prfx.byspotify.com/e/media.transistor.fm/c7970701/0ccda55d.mp3 Processing state: not_requested JSON: https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/iv-iron-risks-and-low-dose-aml-gains Duration seconds: 1488 ## Resource In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood . Dr. Zoller discusses " Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia ", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications. Dr. Ribeiro discusses " A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial " and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings. ## Actions - request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/iv-iron-risks-and-low-dose-aml-gains/transcription-requests` — Idempotently request low-priority transcript generation for this episode. - read_markdown: `GET https://stenobird.com/podcast/blood-podcast-664776/iv-iron-risks-and-low-dose-aml-gains.md` — Read the agent-friendly Markdown representation of this episode resource. A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed. ## Transcript Full transcripts are not published on public pages unless there is a clear rights basis.